Myungsun Shim1, Cheryn Song2, Sejun Park3, Seung-Kwon Choi4, Yong Mee Cho5, Choung-Soo Kim6, Hanjong Ahn6. 1. Department of Urology, Hallym University Sacred Heart Hospital, Hallym University College of Medicine, Anyang, GyeongGi-Do, Korea. 2. Department of Urology, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea. cherynsong@amc.seoul.kr. 3. Department of Urology, University of Ulsan College of Medicine, Ulsan University Hospital, Ulsan, Korea. 4. Department of Urology, School of Medicine, Kyung Hee University, Seoul, Korea. 5. Department of Pathology, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea. 6. Department of Urology, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea.
Abstract
PURPOSE: We investigated the expression status of vascular endothelial growth factor (VEGF), platelet-derived growth factor (PDGF)-B and their receptors in organ-confined clear cell renal cell carcinoma (ccRCC) to evaluate their prognostic significance after radical surgery. METHODS: In 758 consecutive patients diagnosed with pT1-2N0 ccRCC between 2007 and 2012, we prospectively investigated the expression levels of VEGF, PDGF-B, VEGF receptor (VEGFR) and PDGF receptor (PDGFR)-β via immunohistochemistry. Clinicopathologic parameters and expression of the angiogenic factors were analyzed with respect to recurrence-free survival (RFS) after nephrectomy. The median follow-up was 29.5 months (IQR 21.5, 39.6) after surgery. RESULTS: Partial nephrectomy had been performed in 48.5 % of the patients, and tumors were staged as pT1a in 514 (67.8 %), pT1b in 192 (25.3 %) and pT2 in 52 (6.9 %). VEGF, PDGF and their receptors were identified in the cytoplasm and membranes of the tumor cells. Expression level of VEGFR inversely correlated with both tumor size (r = -0.076, p = 0.014) and nuclear grade (r = -0.297, p = 0.004). As for PDGF-B, the expression level showed an inverse correlation with tumor size (r = -0.216, p < 0.001) while PDGFR-β inversely correlated with nuclear grade (r = -0.341, p = 0.001). On multivariate analysis, age, pathologic stage, nuclear grade and PDGFR-β expression (high vs. low or none, HR 3.121 95 % CI 1.300-7.493, p = 0.011) were independently prognostic of RFS after nephrectomy. CONCLUSIONS: In organ-confined ccRCC, high expression of PDGFR-β was independently predictive of poorer RFS after nephrectomy.
PURPOSE: We investigated the expression status of vascular endothelial growth factor (VEGF), platelet-derived growth factor (PDGF)-B and their receptors in organ-confined clear cell renal cell carcinoma (ccRCC) to evaluate their prognostic significance after radical surgery. METHODS: In 758 consecutive patients diagnosed with pT1-2N0 ccRCC between 2007 and 2012, we prospectively investigated the expression levels of VEGF, PDGF-B, VEGF receptor (VEGFR) and PDGF receptor (PDGFR)-β via immunohistochemistry. Clinicopathologic parameters and expression of the angiogenic factors were analyzed with respect to recurrence-free survival (RFS) after nephrectomy. The median follow-up was 29.5 months (IQR 21.5, 39.6) after surgery. RESULTS: Partial nephrectomy had been performed in 48.5 % of the patients, and tumors were staged as pT1a in 514 (67.8 %), pT1b in 192 (25.3 %) and pT2 in 52 (6.9 %). VEGF, PDGF and their receptors were identified in the cytoplasm and membranes of the tumor cells. Expression level of VEGFR inversely correlated with both tumor size (r = -0.076, p = 0.014) and nuclear grade (r = -0.297, p = 0.004). As for PDGF-B, the expression level showed an inverse correlation with tumor size (r = -0.216, p < 0.001) while PDGFR-β inversely correlated with nuclear grade (r = -0.341, p = 0.001). On multivariate analysis, age, pathologic stage, nuclear grade and PDGFR-β expression (high vs. low or none, HR 3.121 95 % CI 1.300-7.493, p = 0.011) were independently prognostic of RFS after nephrectomy. CONCLUSIONS: In organ-confined ccRCC, high expression of PDGFR-β was independently predictive of poorer RFS after nephrectomy.
Authors: Brett Delahunt; John M Kittelson; Margaret R E McCredie; Anthony E Reeve; John H Stewart; A Michael Bilous Journal: Cancer Date: 2002-02-01 Impact factor: 6.860
Authors: Ossama W Tawfik; Brandan Kramer; Barbara Shideler; Marsha Danley; Bruce F Kimler; Jeffrey Holzbeierlein Journal: Arch Pathol Lab Med Date: 2007-02 Impact factor: 5.534
Authors: Jamie M Aye; Laura L Stafman; Adele P Williams; Evan F Garner; Jerry E Stewart; Joshua C Anderson; Smitha Mruthyunjayappa; Mary G Waldrop; Caroline D Goolsby; Hooper R Markert; Colin Quinn; Raoud Marayati; Elizabeth Mroczek-Musulman; Christopher D Willey; Karina J Yoon; Kimberly F Whelan; Elizabeth A Beierle Journal: Oncotarget Date: 2019-09-17